{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-027191","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.454877+00:00","generated_at":"2026-05-17T11:56:04.894226+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex gets US and EU patent allowances for REQORSA combo with PD-L1/PD-1 antibodies; trial underway","bullets":["USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.","Korea granted patent for REQORSA + PD-L1 antibodies; Genprex pursuing additional patents in Europe, Canada, Brazil, China, Israel for Acclaim-3 trial.","Patents for REQORSA + PD-1 antibodies already granted in US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.","Acclaim-3 Phase 1/2 trial testing REQORSA + Tecentriq maintenance in ES-SCLC has FDA Fast Track and Orphan Drug Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-027191","json":"https://secwatch.observer/filing/0001437749-25-027191.json","markdown":"https://secwatch.observer/filing/0001437749-25-027191.md","text":"https://secwatch.observer/filing/0001437749-25-027191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/0001437749-25-027191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/gnpx20250815_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:56:04.894226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}